Omnicell (OMCL) shares came into focus after its latest earnings, where revenue aligned with expectations but non-GAAP profitability fell short as the company increased spending on new products and customer experience initiatives.

The latest earnings update and guidance come after a sharp 30 day share price decline of 27.75%, while a 1 year total shareholder return loss of 7.85% and a 5 year total shareholder return loss of 72.12% point to longer term momentum that has been weak, despite a 90 day share price gain of 6.76%.

If earnings volatility around Omnicell has you reassessing healthcare tech, this is a good moment to look at our screener of 25 healthcare AI stocks as potential alternatives to research next.

With revenue holding up but earnings under pressure, and the share price well below analyst targets and some intrinsic value estimates, the key question is whether Omnicell is on sale or whether the market already reflects its future growth.

Most Popular Narrative: 29.1% Undervalued

Omnicell's most followed narrative pegs fair value at $51.50 per share, comfortably above the last close of $36.50. This puts a spotlight on its medication management platform shift.

The continued rollout and adoption of the cloud-native OmniSphere platform across Omnicell's customer base will simplify enterprise-wide medication management, make adding new features and integrating advanced analytics much easier, and accelerate the company's transition to higher-margin, recurring SaaS-based revenues, supporting improved revenue predictability and net margins.

Want to see what is behind that confidence in recurring revenue and margins? The narrative leans on measured growth, rising profitability, and a richer future earnings multiple that has to be justified by those forecasts. Curious how all of that math supports a fair value above $50?

Result: Fair Value of $51.50 (UNDERVALUED)

However, tariff related costs and any slowdown in hospitals' capital spending could pressure margins and delay the recurring revenue shift that underpins the $51.50 narrative.

Build Your Own Omnicell Narrative

If this version of the story does not quite match your view, or you prefer to test your own assumptions against the data, you can build a complete Omnicell thesis yourself in just a few minutes. Start with Do it your way.

A great starting point for your Omnicell research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.

Looking for more investment ideas?

If Omnicell is only one piece of your watchlist, now is the time to line up a few more quality candidates before the next round of earnings headlines hits.

• Target potential value opportunities by scanning our list of 53 high quality undervalued stocks that combine quality fundamentals with prices that some investors may consider attractive.
• Strengthen your portfolio core by focusing on companies highlighted in our solid balance sheet and fundamentals stocks screener (45 results) that could help you sleep better when volatility picks up.
• Spot tomorrow's potential standouts early by reviewing our screener containing 23 high quality undiscovered gems, a collection of under the radar names supported by solid fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.